Michael Schmitz Analyst PerformanceSenior Managing Director & Equity Research Analyst at GuggenheimMichael Schmitz is a stock analyst at Guggenheim focused in the healthcare sector, covering 11 publicly traded companies. Over the past year, Michael Schmitz has issued 10 stock ratings, including buy and hold recommendations. While full access to Michael Schmitz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Schmitz's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings14 Last 9 YearsBuy Recommendations71.43% 10 Buy RatingsCompanies Covered11 Unique Companies Ratings Distribution14RatingsDistribution of strong buy, buy, hold, and sell ratings by Michael Schmitz.RatingPercentageCount Strong Buy0.0%0 ratings Buy71.4%10 ratings Hold28.6%4 ratings Sell0.0%0 ratingsOut of 14 total stock ratings issued by Michael Schmitz at Guggenheim, the majority (71.4%) have been Buy recommendations, followed by 28.6% Hold.Best & Worst CallsBest Call000.0%EXELJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%EQTAug 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ72.7% of companies on NASDAQ8 companiesNYSE27.3% of companies on NYSE3 companiesMichael Schmitz, an analyst at Guggenheim, currently covers 11 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare8 companies72.7%Energy3 companies27.3%Michael Schmitz of Guggenheim specializes in stock coverage within the Healthcare sector, with additional focus on Energy companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY7 companies63.6%OIL, GAS & CONSUMABLE FUELS3 companies27.3%PHARMACEUTICALS1 company9.1% About Michael SchmitzDr. Schmidt is a Senior Managing Director and Equity Research Analyst covering the Biotechnology sector based in Guggenheim’s Boston office. With over 17 years of Wall Street experience, Dr. Schmidt joined Guggenheim from Leerink Partners in 2018 where he was a Senior Biotechnology Research Analyst. Previously, he was a healthcare analyst and consultant at Susquehanna International Group’s private equity team in San Francisco and a research fellow at Harvard University. Dr. Schmidt earned his M.S. in Biology and Ph.D. in Biochemistry at the University of Stuttgart, Germany. Dr. Schmidt was named runner-up in the 2017 Institutional Investor All-America Research Survey, Biotechnology/Mid- & Small-Cap.Follow on LinkedIn Michael Schmitz's Ratings History at Guggenheim Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsRVMDRevolution Medicines8/28/2026Boost Price Target$221.15$275.00Buy$0.0000.00% ROIAVBPArriVent BioPharma8/13/2026Reiterated Rating$29.85$45.00Buy$0.0000.00% ROIELVNEnliven Therapeutics8/6/2026Lower Price Target$59.70$78.00Buy$0.0000.00% ROIONCBeOne Medicines8/6/2026Boost Price Target$331.99$430.00Buy$0.0000.00% ROIERASErasca1/27/2026Reiterated Rating$9.61$12.00Buy$0.0000.00% ROIERASErasca11/14/2025Boost Price Target$2.68$5.00Buy$0.0000.00% ROIMRSNMersana Therapeutics11/14/2025Downgrade$27.26Hold$0.0000.00% ROIEXELExelixis11/3/2025Downgrade$38.67Neutral$0.0000.00% ROIMRUSMerus9/30/2025Reiterated Rating$93.61$97.00Neutral$0.0000.00% ROIMRUSMerus9/29/2025Downgrade$94.15Hold$0.0000.00% ROIEXELExelixis7/29/2025Reiterated Rating$37.59$45.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenRoth CapitalCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
